{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:55:55Z","timestamp":1789692955582,"version":"4.0.1"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["GPO-A-00-04-00019-00"],"award-info":[{"award-number":["GPO-A-00-04-00019-00"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT\u2019s preclinical safety, lack of systemic absorption after vaginal administration in animal studies, and lack of cross-resistance with existing ARV drugs prompted its development for topical HIV PrEP. We investigated safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of PC-6500 (0.1% GRFT in a carrageenan (CG) gel) in healthy women after vaginal administration. This randomized, placebo-controlled, parallel group, double-blind first-in-human phase 1 study enrolled healthy, HIV-negative, non-pregnant women aged 24\u201345 years. In the open label period, all participants (n = 7) received single dose of PC-6500. In the randomized period, participants (n = 13) were instructed to self-administer 14 doses of PC-6500 or its matching CG placebo (PC-535) once daily for 14 days. The primary outcomes were safety and PK after single dose, and then after 14 days of dosing. Exploratory outcomes were GRFT concentrations in cervicovaginal fluids, PD, inflammatory mediators and gene expression in ectocervical biopsies. This trial is registered with ClinicalTrials.gov, number NCT02875119. No significant adverse events were recorded in clinical or laboratory results or histopathological evaluations in cervicovaginal mucosa, and no anti-drug (GRFT) antibodies were detected in serum. No cervicovaginal proinflammatory responses and no changes in the ectocervical transcriptome were evident. Decreased levels of proinflammatory chemokines (CXCL8, CCL5 and CCL20) were observed. GRFT was not detected in plasma. GRFT and GRFT\/CG in cervicovaginal lavage samples inhibited HIV and HPV, respectively, <jats:italic>in vitro<\/jats:italic> in a dose-dependent fashion. These data suggest GRFT formulated in a CG gel is a safe and promising on-demand multipurpose prevention technology product that warrants further investigation.<\/jats:p>","DOI":"10.1371\/journal.pone.0261775","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T18:25:10Z","timestamp":1642703110000},"page":"e0261775","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-4650","authenticated-orcid":true,"given":"Natalia","family":"Teleshova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-4000","authenticated-orcid":true,"given":"Marla J.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Fern\u00e1ndez Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6645-4238","authenticated-orcid":true,"given":"George W.","family":"Creasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena G.","family":"Plagianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Barnable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Kizima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixa","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-0152","authenticated-orcid":true,"given":"Nadjet","family":"Cornejal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-8713","authenticated-orcid":true,"given":"Gearoff","family":"Cruz Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-765X","authenticated-orcid":true,"given":"Sampurna","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Calenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta U.","family":"Sinkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Bonnaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asa","family":"Wesenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-2116","authenticated-orcid":true,"given":"Kyle","family":"Kleinbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohcine","family":"Alami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-4856","authenticated-orcid":true,"given":"Barry R.","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gillevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-9188","authenticated-orcid":true,"given":"Hong","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-463X","authenticated-orcid":true,"given":"Yupu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-4653","authenticated-orcid":true,"given":"Gabriela","family":"Santone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-5735","authenticated-orcid":true,"given":"Raina N.","family":"Fichorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2370-0961","authenticated-orcid":true,"given":"Tamara","family":"Kalir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Zydowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"pone.0261775.ref001","unstructured":"http:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"issue":"27","key":"pone.0261775.ref002","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0261775.ref003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"151","key":"pone.0261775.ref004","doi-asserted-by":"crossref","first-page":"151ra25","DOI":"10.1126\/scitranslmed.3004006","article-title":"Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men","volume":"4","author":"PL Anderson","year":"2012","journal-title":"Sci Transl Med"},{"issue":"9","key":"pone.0261775.ref005","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1016\/S2352-3018(17)30089-9","article-title":"Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study","volume":"4","author":"JM Molina","year":"2017","journal-title":"Lancet HIV"},{"issue":"5","key":"pone.0261775.ref006","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0261775.ref007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"JM Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0261775.ref008","unstructured":"https:\/\/www.hptn.org\/news-and-events\/press-releases\/hptn-083-study-demonstrates-superiority-cabotegravir-prevention-hiv"},{"key":"pone.0261775.ref009","unstructured":"https:\/\/www.hptn.org\/news-and-events\/press-releases\/hptn-084-study-demonstrates-superiority-of-cab-la-to-oral-tdfftc-for"},{"issue":"7","key":"pone.0261775.ref010","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10461-016-1407-9","article-title":"Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population","volume":"20","author":"HA Kwakwa","year":"2016","journal-title":"AIDS Behav"},{"issue":"1","key":"pone.0261775.ref011","doi-asserted-by":"crossref","first-page":"20875","DOI":"10.7448\/IAS.19.1.20875","article-title":"Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study","volume":"19","author":"EH Luecke","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0261775.ref012","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/QAI.0000000000000880","article-title":"Participants\u2019 Explanations for Nonadherence in the FEM-PrEP Clinical Trial","volume":"71","author":"A Corneli","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"pone.0261775.ref013","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1227","article-title":"HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise","volume":"104","author":"CW Hendrix","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"pone.0261775.ref014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","article-title":"Use of modern contraception increases when more methods become available: analysis of evidence from 1982\u20132009","volume":"1","author":"J Ross","year":"2013","journal-title":"Glob Health Sci Pract"},{"issue":"1","key":"pone.0261775.ref015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine","volume":"214","author":"ML Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0261775.ref016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/COH.0000000000000232","article-title":"Genital inflammation, immune activation and risk of sexual HIV acquisition","volume":"11","author":"JA Passmore","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"pone.0261775.ref017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12889-020-8195-x","article-title":"Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria","volume":"20","author":"G Emmanuel","year":"2020","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0261775.ref018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12879-018-3415-z","article-title":"Acceptability of HIV self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia: results from two randomized controlled trials","volume":"18","author":"KF Ortblad","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0261775.ref019","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1007\/s10461-018-2045-1","article-title":"Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men","volume":"22","author":"THF Whitfield","year":"2018","journal-title":"AIDS Behav"},{"issue":"15","key":"pone.0261775.ref020","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1073\/pnas.0901506106","article-title":"Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component","volume":"106","author":"BR O\u2019Keefe","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pone.0261775.ref021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/095632020901900401","article-title":"The future of HIV microbicides: challenges and opportunities","volume":"19","author":"AB Garg","year":"2009","journal-title":"Antivir Chem Chemother"},{"issue":"4","key":"pone.0261775.ref022","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jama.1992.03490040053025","article-title":"Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes","volume":"268","author":"J Kreiss","year":"1992","journal-title":"JAMA"},{"issue":"8","key":"pone.0261775.ref023","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJM199808203390803","article-title":"A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases","volume":"339","author":"RE Roddy","year":"1998","journal-title":"N Engl J Med"},{"issue":"9338","key":"pone.0261775.ref024","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(02)11079-8","article-title":"Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial","volume":"360","author":"L Van Damme","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"pone.0261775.ref025","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/QAD.0b013e32834541d9","article-title":"Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women","volume":"25","author":"SS Abdool Karim","year":"2011","journal-title":"AIDS"},{"issue":"9654","key":"pone.0261775.ref026","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0140-6736(08)61842-5","article-title":"Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"372","author":"S Skoler-Karpoff","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"pone.0261775.ref027","doi-asserted-by":"crossref","first-page":"e3784","DOI":"10.1371\/journal.pone.0003784","article-title":"Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria","volume":"3","author":"V Halpern","year":"2008","journal-title":"PLoS One"},{"issue":"5","key":"pone.0261775.ref028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa0707957","article-title":"Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission","volume":"359","author":"L Van Damme","year":"2008","journal-title":"N Engl J Med"},{"issue":"9749","key":"pone.0261775.ref029","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(10)61086-0","article-title":"PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial","volume":"376","author":"S McCormack","year":"2010","journal-title":"Lancet"},{"issue":"17","key":"pone.0261775.ref030","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1128\/JVI.02675-10","article-title":"Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site","volume":"85","author":"KB Alexandre","year":"2011","journal-title":"J Virol"},{"issue":"10","key":"pone.0261775.ref031","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"T Mori","year":"2005","journal-title":"J Biol Chem"},{"issue":"7","key":"pone.0261775.ref032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tim.2015.02.006","article-title":"Multipurpose prevention technologies: the future of HIV and STI protection","volume":"23","author":"JA Fernandez-Romero","year":"2015","journal-title":"Trends Microbiol"},{"issue":"11","key":"pone.0261775.ref033","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1128\/JVI.00012-13","article-title":"Griffithsin protects mice from genital herpes by preventing cell-to-cell spread","volume":"87","author":"B Nixon","year":"2013","journal-title":"J Virol"},{"issue":"12","key":"pone.0261775.ref034","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/AAC.01816-15","article-title":"Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus","volume":"59","author":"K Levendosky","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0261775.ref035","doi-asserted-by":"crossref","first-page":"e1003495","DOI":"10.1371\/journal.pmed.1003495","article-title":"Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial","volume":"18","author":"JA Politch","year":"2021","journal-title":"PLoS Med"},{"issue":"12","key":"pone.0261775.ref036","doi-asserted-by":"crossref","first-page":"e116153","DOI":"10.1371\/journal.pone.0116153","article-title":"MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide","volume":"9","author":"GC Morris","year":"2014","journal-title":"PLoS One"},{"key":"pone.0261775.ref037","unstructured":"https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"issue":"8","key":"pone.0261775.ref038","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.olq.0000135986.35216.ba","article-title":"Assay for establishing whether microbicide applicators have been exposed to the vagina","volume":"31","author":"A Wallace","year":"2004","journal-title":"Sex Transm Dis"},{"issue":"1","key":"pone.0261775.ref039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.contraception.2006.10.012","article-title":"Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials","volume":"76","author":"AR Wallace","year":"2007","journal-title":"Contraception"},{"issue":"11","key":"pone.0261775.ref040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1089\/aid.2015.0006","article-title":"Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity","volume":"31","author":"AR Thurman","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"Suppl 3","key":"pone.0261775.ref041","first-page":"S184","article-title":"Guiding the vaginal microbicide trials with biomarkers of inflammation","volume":"37","author":"RN Fichorova","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"pone.0261775.ref042","first-page":"105","article-title":"Interferences in immunoassay","volume":"25","author":"J Tate","year":"2004","journal-title":"Clin Biochem Rev"},{"issue":"9","key":"pone.0261775.ref043","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1128\/AAC.00392-16","article-title":"In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa","volume":"60","author":"G Villegas","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0261775.ref044","doi-asserted-by":"crossref","first-page":"13494","DOI":"10.1038\/s41598-019-49647-3","article-title":"Comparative transcriptome analysis of the human endocervix and ectocervix during the proliferative and secretory phases of the menstrual cycle","volume":"9","author":"S Mukhopadhyay","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0261775.ref045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1089\/aid.2010.0252","article-title":"Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro","volume":"27","author":"O Begay","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"pone.0261775.ref046","doi-asserted-by":"crossref","first-page":"e94547","DOI":"10.1371\/journal.pone.0094547","article-title":"A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV","volume":"9","author":"L Kizima","year":"2014","journal-title":"PLoS One"},{"key":"pone.0261775.ref047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2014.05.018","article-title":"In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition","volume":"108","author":"A Rodriguez","year":"2014","journal-title":"Antiviral Res"},{"issue":"9","key":"pone.0261775.ref048","doi-asserted-by":"crossref","first-page":"e108109","DOI":"10.1371\/journal.pone.0108109","article-title":"A MIV-150\/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explants","volume":"9","author":"P Barnable","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"pone.0261775.ref049","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1128\/JCM.00673-09","article-title":"Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis","volume":"47","author":"N Richardson-Harman","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"11","key":"pone.0261775.ref050","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/aid.2012.0080","article-title":"The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian\/human immunodeficiency virus-RT Infection","volume":"28","author":"M Aravantinou","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"pone.0261775.ref051","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"MD Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"5","key":"pone.0261775.ref052","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/aid.2015.0088","article-title":"Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1","volume":"32","author":"C Mauck","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"pone.0261775.ref053","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.contraception.2006.02.008","article-title":"Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study","volume":"74","author":"JL Schwartz","year":"2006","journal-title":"Contraception"},{"issue":"1","key":"pone.0261775.ref054","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1038\/s41467-018-06349-0","article-title":"Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo","volume":"9","author":"N Derby","year":"2018","journal-title":"Nat Commun"},{"issue":"7241","key":"pone.0261775.ref055","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/nature07831","article-title":"Glycerol monolaurate prevents mucosal SIV transmission","volume":"458","author":"Q Li","year":"2009","journal-title":"Nature"},{"issue":"7","key":"pone.0261775.ref056","doi-asserted-by":"crossref","first-page":"e0129769","DOI":"10.1371\/journal.pone.0129769","article-title":"Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study","volume":"10","author":"K Smith-McCune","year":"2015","journal-title":"PLoS One"},{"issue":"6294","key":"pone.0261775.ref057","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/347669a0","article-title":"Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES","volume":"347","author":"TJ Schall","year":"1990","journal-title":"Nature"},{"key":"pone.0261775.ref058","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-4615-2952-1_15","article-title":"The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets","volume":"351","author":"DD Taub","year":"1993","journal-title":"Adv Exp Med Biol"},{"issue":"5243","key":"pone.0261775.ref059","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","article-title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells","volume":"270","author":"F Cocchi","year":"1995","journal-title":"Science"},{"issue":"7","key":"pone.0261775.ref060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1089\/omi.2019.0092","article-title":"A New Approach to Measure Adherence to Medicines Using Biomarkers and Sensors","volume":"23","author":"V Ozdemir","year":"2019","journal-title":"OMICS"},{"issue":"5","key":"pone.0261775.ref061","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/QAI.0b013e318271c8f9","article-title":"Carrageenan-based gel retains limited anti-HIV-1 activity 8\u201324 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial","volume":"61","author":"RE Haaland","year":"2012","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T18:25:50Z","timestamp":1642703150000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261775"}},"subtitle":[],"editor":[{"given":"Zandrea","family":"Ambrose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261775","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}